Free Trial
→ I'm handing you this one free (From Behind the Markets) (Ad)tc pixel
OTCMKTS:ANEB

Anebulo Pharmaceuticals Earnings Date & Estimates

Anebulo Pharmaceuticals logo
$0.26 -0.03 (-9.45%)
As of 09:40 AM Eastern

Anebulo Pharmaceuticals is estimated to report earnings on Wednesday, November 18, 2026.

Research:ProfileEarnings History

Upcoming Earnings Announcement

Announcement Date
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Anebulo Pharmaceuticals

Anebulo Pharmaceuticals is expected to post earnings of -$0.11 per share. In the same quarter a year earlier Anebulo Pharmaceuticals reported -$0.05 per share. Anebulo Pharmaceuticals last reported on February 13, 2026, posting -$0.05 per share and beating the -$0.13 consensus estimate. Anebulo Pharmaceuticals has beaten the consensus EPS estimate in 6 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.11
Prior-Year EPS
-$0.05

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.05 (Beat by +$0.08)
EPS Beat Rate
6 of last 8 quarters

Prepare for the Earnings Call

Anebulo Pharmaceuticals Earnings FAQ

Anebulo Pharmaceuticals (OTCMKTS:ANEB) is estimated to report earnings on Wednesday, November 18, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

Analysts expect Anebulo Pharmaceuticals to post earnings of -$0.11 per share for the quarter.

Anebulo Pharmaceuticals Earnings Headlines

ANEBULO PHARMAC INC by Anebulo Pharmaceuticals Inc (ANEB) Stock Price, Quote, News & History
July 1, 2026  |  benzinga.comhttps://www.benzinga.com/quote/ANEB
Anebulo’s Selonabant Phase 1 Completion: What Investors Should Watch Next
May 8, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/anebulos-selonabant-phase-1-completion-what-investors-should-watch-next?utm_source=marketbeat.com&utm_medium=referral
The Withdrawal You'll Never See on Your Statement
A proposal circulating in Washington, dubbed the Mar-a-Lago Accord, calls for tariffs and currency pressure to deliberately weaken the US dollar, making American exports cheaper. For savers, a weaker dollar can quietly reduce purchasing power even if account balances stay the same. Bishop Gold Group's free 2026 Gold IRA Guide explains how physical gold can be held inside a retirement account, including a common rollover mistake that can trigger a taxable distribution.tc pixel
November 10 at 1:00 AM  |  Bishop Gold Group (Ad)
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Updates
February 13, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/news/anebulo-pharmaceuticals-reports-second-quarter-211500245.html
Anebulo Pharmaceuticals stock plunges after announcing Nasdaq delisting plans
February 6, 2026  |  in.investing.comhttps://in.investing.com/news/stock-market-news/anebulo-pharmaceuticals-stock-plunges-after-announcing-nasdaq-delisting-plans-93CH-5227099
Anebulo Pharmaceuticals Announces Intention to Voluntarily Delist from Nasdaq and Deregister with SEC
February 6, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/news/anebulo-pharmaceuticals-announces-intention-voluntarily-140000001.html
See More Anebulo Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Anebulo Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Anebulo Pharmaceuticals and other key companies, straight to your email.

About Anebulo Pharmaceuticals

Anebulo Pharmaceuticals (OTCMKTS:ANEB) is a clinical-stage biopharmaceutical company focused on developing treatments for acute cannabinoid intoxication and related medical emergencies. The company’s work is aimed at addressing the effects of cannabis and synthetic cannabinoids, including situations in which patients require urgent medical care.

Anebulo’s lead investigational product, ANEB-001, is an orally administered antagonist of the cannabinoid type 1 (CB1) receptor. The company is developing ANEB-001 to rapidly reverse the effects of cannabinoid intoxication, with potential applications in emergency and acute-care settings. The product remains investigational and has not been approved for commercial use.

Based in Austin, Texas, Anebulo conducts its development activities through clinical research and pharmaceutical collaborations. The company was established to pursue therapies for acute cannabinoid-related conditions and is led by Chief Executive Officer Simon Allen.

View Anebulo Pharmaceuticals Profile
Earnings Tools